The patent application covers methods to improve walking in patients with multiple sclerosis (MS) by administering 10mg of sustained release 4-aminopyridine (dalfampridine) twice daily.
Acorda is marketing Ampyra (dalfampridine) extended release tablets, 10 mg as a treatment to improve walking in people with MS.